Glaucoma
Conditions
Brief summary
Evaluate the relative efficacy and tolerability of Alphagan P compared to Trusopt as adjunctive therapy
Interventions
DRUGBrimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost
Sponsors
Innovative Medical
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
SINGLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* · Male or female \> 18 years of age * Diagnosis of open-angle glaucoma or ocular hypertension * IOP \> 16 mm Hg in each eye at the latanoprost -treated baseline evaluation * Presently on latanoprost monotherapy for at least 6 weeks * Ability to provide informed consent and likely to complete all study visits
Exclusion criteria
* · Known contraindication or allergy to brimonidine or any of its components * Subjects must be naive to brimonidine 0.2% or brimonidine Purite 0.15% and dorzolamide 2% * Uncontrolled systemic disease * Active ocular disease other than glaucoma or ocular hypertension (e.g. uveitis, ocular infections, or severe dry eye). Patients with chronic mild blepharitis, cataract, age-related macular degeneration, or background diabetic retinopathy may be enrolled at the discretion of the investigator. * Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear product is allowed). * Corneal abnormalities * History of intraocular surgery within the last 3 months * Female patients of childbearing potential who are pregnant, lactating, planning a pregnancy, or not using a reliable form of birth control * Visual field loss, which in the opinion of the investigator, is functionally significant, or evidence of progressive visual field loss within the last year.
Countries
United States
Outcome results
None listed